ClinicalTrials.gg
CompletedNCT01746979MAESTROUpdated May 11, 2025Results posted

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

A Phase 3 interventional study of TH-302 and Gemcitabine in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by ImmunoGenesis. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by ImmunoGenesis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
693
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
64th of 1,863
693 · median 43
Started
2012
with 73 others
Phase 3
164 of 2,054
21 open now
Registered
824th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 64th largest by enrollment of the 1,863 interventional ones that give a count, is one of 74 that started in 2012, is one of 164 in phase 3, and was the 824th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in combination with TH-302 compared to gemcitabine in combination with placebo in subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma. Randomized subjects will receive TH-302 plus gemcitabine or gemcitabine plus placebo in 4-week cycles until there is evidence of progressive disease, intolerable toxicity, or the subject discontinues from the trial for other reasons (for example, withdrawal of consent). The primary efficacy endpoint is overall survival (OS) time. The data cut-off for statistical analyses of the primary and secondary endpoints will be reached when 508 events (deaths) will be reported. No planned interim analyses will be conducted. An Independent Safety Monitoring Board (ISMB) will provide periodic evaluations of the unblinded safety data to ensure subject safety and the validity and scientific merit of the study. A total of 660 subjects will be enrolled.

03

Conditions studied

  • Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

Keywords

  • TH-302
  • Evofosfamide
  • Pancreatic Cancer
  • EMR200592-001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Locally advanced unresectable or pancreatic ductal adenocarcinoma proven by histology or cytology and previously untreated with chemotherapy or systemic therapy other than:

    • Radiosensitizing doses of 5-fluorouracil;
    • Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine;
    • chemotherapy if relapse occurred at least 6 months after surgical resection;
    • Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy
  • (at least one target lesion outside of previous radiation fields) or non-measurable disease by v.1.1 criteria
  • Documentation of disease progression since any prior therapy
  • (ECOG) performance status of 0 or 1.
  • of at least 3 month
  • Acceptable liver, renal function and acceptable hematological status
  • Other protocol defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • (NYHA) Class III or IV congestive heart failure, myocardial infarction within 6 months prior to the date of randomization, unstable arrhythmia or symptomatic peripheral arterial vascular disease
  • Symptomatic ischemic heart disease
  • Known brain, or epidural (unless treated and well controlled for at least 3 months)
  • Previous other than pancreatic cancer in the last 5 years, except for adequately treated non-melanoma skin cancer or pre-invasive cancer of the cervix
  • Severe chronic obstructive or other pulmonary disease with hypoxemia
  • Major surgery, other than diagnostic surgery, less than or equal to 28 days prior to the date of randomization. Subject must have completely recovered from surgery
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Treatment of pancreatic cancer with radiation therapy or surgery less than or equal to 28 days prior to the date of randomization
  • Prior therapy with a hypoxic cytotoxin
  • Subjects who participated in an drug or device trial less than or equal to 28 days prior to Day 1 of the first cycle
  • Known infection with (HIV), or an active infection with or
  • Subjects who have exhibited allergic reactions to a structural compound similar to TH-302 or the drug product or to gemcitabine or its excipients
  • Other protocol defined exclusion criteria may apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
693 participants (actual)

Study arms

  • Active comparator
    Gemcitabine plus TH-302

    Drug: TH-302 · Drug: Gemcitabine

  • Placebo comparator
    Gemcitabine plus placebo

    Drug: Gemcitabine · Drug: Placebo (5 percent dextrose - D5W)

Interventions

  • DrugTH-302

    TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.

  • Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.

  • DrugPlacebo (5 percent dextrose - D5W)

    TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival is defined as time from randomization to death or last day known to be alive.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

Secondary outcomes

  1. Progression Free Survival

    Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

07

Results

Posted Dec 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine Plus TH-302Gemcitabine Plus Placebo
Started346347
Completed00
Not completed346347

Outcome measures

PrimaryOverall Survival

Overall survival is defined as time from randomization to death or last day known to be alive.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Reported as:
Median · months
Overall Survival
monthsGemcitabine Plus TH-302Gemcitabine Plus Placebo
Overall Survival8.9 (7.6 to 9.9)7.6 (6.7 to 8.3)
SecondaryProgression Free Survival

Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Reported as:
Median · months
Progression Free Survival
monthsGemcitabine Plus TH-302Gemcitabine Plus Placebo
Progression Free Survival5.5 (4.8 to 5.6)3.7 (3.6 to 3.8)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TH-302—341/341 (100%)341/341 (100%)
Placebo—338/338 (100%)338/338 (100%)
Most frequent serious events
Showing 10 of 250
Most frequent serious events
EventTH-302Placebo
ThrombocytopeniaBlood and lymphatic system disorders0/34119/338
AnaemiaBlood and lymphatic system disorders15/34116/338
CholangitisHepatobiliary disorders15/34112/338
PyrexiaGeneral disorders11/34114/338
General physical health deteriorationGeneral disorders14/34111/338
VomitingGastrointestinal disorders13/3417/338
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/34111/338
Abdominal painGastrointestinal disorders7/34110/338
NeutropeniaBlood and lymphatic system disorders1/3419/338
PneumoniaInfections and infestations9/3418/338
Most frequent other events
Showing 10 of 24
Most frequent other events
EventTH-302Placebo
NauseaGastrointestinal disorders150/341168/338
AnaemiaBlood and lymphatic system disorders108/341164/338
ThrombocytopeniaBlood and lymphatic system disorders61/341158/338
NeutropeniaBlood and lymphatic system disorders94/341140/338
Decreased appetiteMetabolism and nutrition disorders116/341117/338
DiarrhoeaGastrointestinal disorders89/341112/338
VomitingGastrointestinal disorders109/341109/338
FatigueGeneral disorders106/34198/338
ConstipationGastrointestinal disorders104/341104/338
Platelet count decreasedInvestigations44/341100/338

Baseline characteristics

Age, Continuous
Age, Continuous(years)Gemcitabine Plus TH-302Gemcitabine Plus PlaceboTotal
Mean65 ± 9.7063.8 ± 9.8264.4 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine Plus TH-302Gemcitabine Plus PlaceboTotal
Female155168323
Male191179370
08

Study locations

2 sites
  • Please Contact U.S. Medical Information
    Rockland, Massachusetts, United States
  • Please Contact Merck Communication Center
    Darmstadt, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Feb 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2012
First posted
Dec 11, 2012
Start
Dec 2012
Primary completionActual
Feb 2016
CompletionActual
May 2016
Results first posted
Dec 2, 2017
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01746979
Lead sponsor
ImmunoGenesis
Collaborators
Threshold Pharmaceuticals
Responsible party
Sponsor
First posted
Dec 11, 2012
Start date
Dec 2012
Primary completion
Feb 2016
Completion
May 2016
Results posted
Dec 2, 2017
Last update
May 11, 2025

Study contacts

Antonio Gualberto, MD, PhD
study director · EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion